SECTOR – HEALTHCARE
RATING – BUY*
MARKET CAP – £19.5m
CURRENT PRICE – 53p# TARGET PRICE – 94p
Initiation of coverage
NORTHLAND VIEW
Global ageing population, a major market: the rapidly ageing population is expected to drive growth in the self-care market
Targeted product portfolio: Venture Life’s portfolio of self-care products is targeted at this fastexpanding group
Growth by acquisition: The UltraDEX portfolio, acquired in 2016, has now been successfully integrated into the Venture Life business, generating a step change in group revenues
Expanding international reach: Venture Life’s products are sold in over 40 countries worldwide and the group’s reach is growing every year
Valuation: we initiate coverage with a 94p price target
The self-care segment is rapidly expanding in the face of growing demand from a rapidly ageing population. Venture Life's portfolio of products directly targets this market. The group recently moved into EBITDA profitability, with growth being driven both organically and by acquisition. We initiate coverage with a BUY recommendation and 94p price target.
COMPANY DESCRIPTION
Venture Life Group plc is a consumer healthcare company. The group develops, manufactures, and commercialises self-care products which target the ageing population.
BEXIMCO PHARMACEUTICALS (LON:BXP)
SECTOR – HEALTHCARE
MARKET CAP – £235m
CURRENT PRICE – 58p#
Northland Capital Partners appointed as sole broker
NORTHLAND VIEW
Beximco Pharma announced the appointment of Northland Capital Partners Limited as sole broker to the Company with immediate effect.
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. Beximco Pharma has over 3,500 employees.
COMPANY DESCRIPTION
Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients.